Mundipharma picks up rights to Herceptin biosimilar Tuznue
The deals allows the firm to market and distribute the drug in selected European countries following its approval
Read More
Tag: Tuznue
EMA gives trastuzumab biosimilar Marketing Authorisation Application
The drug is Prestige’s lead development candidate biosimilar to Roche’s Herceptin.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
